CARISMA THERAPEUTICS INC (CARM) Stock Fundamental Analysis
NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD
Overall CARM gets a fundamental rating of 1 out of 10. We evaluated CARM against 550 industry peers in the Biotechnology industry. CARM may be in some trouble as it scores bad on both profitability and health. CARM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CARM has reported negative net income.
CARM had a negative operating cash flow in the past year.
In the past 5 years CARM always reported negative net income.
CARM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CARM has a Return On Assets of -318.22%. This is amonst the worse of the industry: CARM underperforms 93.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -318.22% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-102.03%
ROA(5y)-64.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CARM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CARM has been increased compared to 1 year ago.
The number of shares outstanding for CARM has been increased compared to 5 years ago.
Compared to 1 year ago, CARM has a worse debt to assets ratio.
2.2 Solvency
CARM has an Altman-Z score of -36.74. This is a bad value and indicates that CARM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -36.74, CARM is not doing good in the industry: 90.18% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -36.74 |
ROIC/WACCN/A
WACC10.61%
2.3 Liquidity
CARM has a Current Ratio of 1.34. This is a normal value and indicates that CARM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.34, CARM is not doing good in the industry: 83.45% of the companies in the same industry are doing better.
CARM has a Quick Ratio of 1.34. This is a normal value and indicates that CARM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.34, CARM is doing worse than 83.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.34 | ||
| Quick Ratio | 1.34 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 33.71% over the past year.
Looking at the last year, CARM shows a very strong growth in Revenue. The Revenue has grown by 31.59%.
The Revenue has been decreasing by -9.56% on average over the past years.
EPS 1Y (TTM)33.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.81%
Revenue 1Y (TTM)31.59%
Revenue growth 3Y-9.56%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
CARM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.26% yearly.
CARM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y54.94%
EPS Next 2Y24.05%
EPS Next 3Y17.34%
EPS Next 5Y10.26%
Revenue Next Year-18.24%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CARM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CARM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CARM's earnings are expected to grow with 17.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.05%
EPS Next 3Y17.34%
5. Dividend
5.1 Amount
CARM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.292
+0.01 (+2.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners31.75%
Inst Owner Change0.76%
Ins Owners1.19%
Ins Owner Change0%
Market Cap12.20M
Analysts80
Price Target1.02 (249.32%)
Short Float %1.91%
Short Ratio0.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-116.57%
Min EPS beat(2)-153.39%
Max EPS beat(2)-79.74%
EPS beat(4)1
Avg EPS beat(4)-59.75%
Min EPS beat(4)-153.39%
Max EPS beat(4)11.02%
EPS beat(8)4
Avg EPS beat(8)-25.91%
EPS beat(12)6
Avg EPS beat(12)-4.47%
EPS beat(16)9
Avg EPS beat(16)41.99%
Revenue beat(2)0
Avg Revenue beat(2)-18.21%
Min Revenue beat(2)-33.92%
Max Revenue beat(2)-2.51%
Revenue beat(4)1
Avg Revenue beat(4)13.49%
Min Revenue beat(4)-39.29%
Max Revenue beat(4)129.7%
Revenue beat(8)4
Avg Revenue beat(8)64.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)-29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.61 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0.48
BVpS-0.88
TBVpS-0.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -318.22% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-102.03%
ROA(5y)-64.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.57% | ||
| Cap/Sales | 0.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.34 | ||
| Quick Ratio | 1.34 | ||
| Altman-Z | -36.74 |
F-Score4
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.81%
EPS Next Y54.94%
EPS Next 2Y24.05%
EPS Next 3Y17.34%
EPS Next 5Y10.26%
Revenue 1Y (TTM)31.59%
Revenue growth 3Y-9.56%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-18.24%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y39.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-501.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-511.3%
OCF growth 3YN/A
OCF growth 5YN/A